Status:
ACTIVE_NOT_RECRUITING
Cardioneuroablation for Variant Angina
Lead Sponsor:
Zhibing Lu
Conditions:
Variant Angina
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Variant angina, also known as vasospastic angina, is a form of chest pain caused by temporary spasms of the coronary arteries, which reduce blood flow to the heart. These spasms often occur at rest an...
Eligibility Criteria
Inclusion
- age between 18 and 80 years;
- variant angina;
- positive ergonovine provocation test;
- refractory to antispasmodic drug therapy, or inability to achieve adequate symptom control due to drug intolerance, poor adherence, or unwillingness to take medications regularly.
Exclusion
- cardiogenic shock;
- chronic heart failure;
- life expectancy less than 12 months;
- current participation in another clinical study without completing the primary endpoint visit; inability to provide informed consent;
- women of childbearing potential without effective contraception or who are breastfeeding;
- coronary artery stenosis ≥50% or FFR ≤0.80;
- sick sinus syndrome or high-degree AV block without pacemaker;
- systolic blood pressure \<90mmHg or heart rate \<50 bpm;
- allergy to diltiazem, nitrates, or nitroglycerin.
Key Trial Info
Start Date :
February 7 2025
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 28 2027
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT06992830
Start Date
February 7 2025
End Date
February 28 2027
Last Update
November 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China, 430071